期刊文献+

有机阴离子转运体1B1和1B3基因多态性对肾移植受者血麦考酚酸浓度的影响 被引量:3

Influence of organic anion transporting potypeptide (SLCO1B1 and SLCO1B3) genetic polymorphisms on mycophenolic acid in Chinese kidney transplantation patients
原文传递
导出
摘要 目的探讨有机阴离子转运体1B1和1B3(编码基因分别为SLCO1B1和SLCO1B3)基因多态性对肾移植受者血麦考酚酸(MPA)浓度的影响。方法用聚合酶链反应一连接酶检测反应法对68例汉族肾移植受者的SLCO1B1和1B3基因进行单核苷酸基因多态性(SNP)检测,分别检测SLCO1B3 T334G和SLCO1B1 A338G的突变位点。术后第28天,收集受者血浆检测MPA浓度。比较各基因型受者的MPA浓度-时间曲线下面积(AUC0-12),分析单核苷酸多态性与MPA AUC0-12:之间的相关性。结果SLCO1B3T334G位点GG基因型受者的MPA AUG0-12高于TT基因型受者,分别为(54.54±14.40)mg·h·L^-1和(37.30±12.88)rng·h·L^-1(P=0.052);SLC0181A338G位点的各个基因型受者之间MPA AUC0-12比较,差异均无统计学意义(P〉O.05)。结论SLCO1B3基因多态性对肾移植受者术后血MPA浓度的个体间差异产生明显影响。 Objective To analyze the relationship between the genetic polymorphisms of organic anion transporting polypeptide (SLCO1B1 and SLCO1B3 ) and mycophenolic acid (MPA) pharmacokinetics in Chinese kidney transplant recipients. Methods Gene mutations (SLCO1B3 T334G, SLCO1B1 A338G) were detected in 68 recipients by PCR-LDR The plasma samples were collected and blood concentration of MPA was measured on the 28 th day after transplantation. The area under the curve (AUC)0-12 of MPA in different genotype recipients was compared to analyze the correlation between single nucleotide polymorphisms (SNPs) and MPA pharmacokinetics. Results MPA AUC0-12 was higher in SLCO1B3 T334G GG carriers group than in TT carriers [(54. 54 ± 14. 40) vs (37. 30 ± 12. 88) mg·h·L^-1 , (P = 0. 052)]. However, there was no difference in MPA AUC0-12 among each genotype of SLCO1B1 A338G (P〉0. 05). Conclusion Genetic polymorphisms of SLCO1B3 affect interindividual variety in plasma MPA concentration in Chinese kidney transplantation recipients.
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2011年第7期393-395,共3页 Chinese Journal of Organ Transplantation
基金 十一五支撑课题,上海市器官移植重点实验室,复旦大学新教师科研启动基金
关键词 肾移植 霉酚酸 有机阴离子转运体多肽 多态性 单核苷酸 Kidney transplantation Mycophenolic Acid Organic anion-transportingpolypeptide Polymorphism, single nucleotide
  • 相关文献

参考文献6

  • 1Allison AC, Eugui EM. Immunosupp ressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev, 1993, 136: 5-28.
  • 2Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy, 1997, 17 (6) : 1178-1197.
  • 3Konig J, Seithel A, Gradhand U, et al. Pharmaeogenomics of human OATP transporters. Naunyn-Schmiedeberg "s Arch Pharmaeol, 2006,372(6) :432-443.
  • 4Baldelli S, Merlini S, Perico N, et ak C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of myeophenolic acid in kidney transplantation. Pharmacogenomies, 2007, 8(9): 1127-1141.
  • 5Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation, 2006, 82(8) : 1074-1084.
  • 6Miura M, SatohS, Inoue K, et al. Influence of SLCX)IB1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol, 2007, 63 (12) : 1161-1169.

同被引文献19

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部